about
The protein interacting with C-kinase (PICK1) interacts with and attenuates parkin-associated endothelial-like (PAEL) receptor-mediated cell deathConsensus analysis of signal peptide peptidase and homologous human aspartic proteases reveals opposite topology of catalytic domains compared with presenilinsRapid and differential regulation of AMPA and kainate receptors at hippocampal mossy fibre synapses by PICK1 and GRIPNeuropathology in mice expressing mouse alpha-synucleinEBI2 regulates intracellular signaling and migration in human astrocyteThe PDZ proteins PICK1, GRIP, and syntenin bind multiple glutamate receptor subtypes. Analysis of PDZ binding motifsMolecular determinants for the complex binding specificity of the PDZ domain in PICK1The protein kinase C alpha binding protein PICK1 interacts with short but not long form alternative splice variants of AMPA receptor subunitsIdentification of novel genes and pathways regulating SREBP transcriptional activityTargeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations.Fingolimod attenuates splenocyte-induced demyelination in cerebellar slice cultures.PDZ proteins interacting with C-terminal GluR2/3 are involved in a PKC-dependent regulation of AMPA receptors at hippocampal synapses.Levels of S100B are raised in female patients with schizophrenia.Part I: parkin-associated proteins and Parkinson's disease.Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.Unraveling in vivo functions of amyloid precursor protein: insights from knockout and knockdown studies.Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.The PSD-95/nNOS complex: new drugs for depression?The structure and function of the S1P1 receptor.The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures.The chemokine fractalkine (CX3CL1) attenuates H2O2-induced demyelination in cerebellar slices.In vitro and ex vivo models of multiple sclerosis.Demyelination induced by oxidative stress is regulated by sphingosine 1-phosphate receptors.Sphingosine-1-phosphate receptor therapies: Advances in clinical trials for CNS-related diseases.Functional expression of the serotonin 5-HT7 receptor in human glioblastoma cell lines.The PDZ domain of PICK1 differentially accepts protein kinase C-alpha and GluR2 as interacting ligands.GABA(B) receptors couple directly to the transcription factor ATF4.Different effects of phospholipase A2 on agonist binding to hippocampal, cortical and recombinant homomeric alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptors.Fractalkine shedding is mediated by p38 and the ADAM10 protease under pro-inflammatory conditions in human astrocytes.Regulation of synaptic strength and AMPA receptor subunit composition by PICK1Small-molecule inhibitors at the PSD-95/nNOS interface have antidepressant-like properties in mice.The EBI2 signalling pathway plays a role in cellular crosstalk between astrocytes and macrophages.Amyloid precursor protein knockdown by siRNA impairs spontaneous alternation in adult mice.Design and synthesis of selective and potent orally active S1P5 agonists.Regulation of kainate receptors by protein kinase C and metabotropic glutamate receptors.The expression of neuronal sorting nexin 8 (SNX8) exacerbates abnormal cholesterol levels.Pro-inflammatory cytokine levels are raised in female schizophrenia patients treated with clozapine.Drug dealers: $20 trillion of in-licensing payments.Phospholipase A2 is involved in galactosylsphingosine-induced astrocyte toxicity, neuronal damage and demyelination.Increased exploratory activity of APP23 mice in a novel environment is reversed by siRNA.
P50
Q24295004-B89323A3-6AA7-4042-96E7-685EAC98CBF4Q24305015-E8EBFDE4-9B93-4D67-9DE0-46A44ADA2566Q24608270-8C43B0E4-ADDB-4BF3-9700-736FA680C52BQ27320029-975A9DA0-E154-4D72-82FF-91500EC917D8Q28116376-BC06CF71-103B-4822-B46A-FCED020FDC6DQ28206704-2CF513C9-1373-457E-8953-8D3CA04FD002Q28569924-C829964B-EFC8-4FA9-9503-B2401BCC19CBQ28579168-F10BA6D7-EFC1-4377-9689-2A67D5F78ADEQ33432792-FA03DBC2-CC6A-49ED-BEA7-C3B42D6CC34EQ33651898-07C922C4-9710-40B5-98F4-F9702E1BB3A1Q33727962-5B6548D9-3B2D-417B-835B-A72C496551DAQ33932164-0CB70064-A9F1-407F-924A-430492449C9CQ34738782-AB97C5E3-504A-4691-AC99-2608B6991A22Q35157619-8CB8AFAE-F2C3-4149-837E-A74FF37E7E54Q35157623-9C250B18-7940-4EFF-B7D1-DD3CD901B6B8Q36586320-4159EAF7-C7DC-4AC2-B38F-2BA191F8C71FQ36981896-CCB5283A-1418-47A7-B943-8A620EDF699AQ37963635-F68FCF1E-F4FD-41E5-9A37-FEF35999E3B6Q38114177-9994F8D1-C040-42DA-B16E-70993FA00B5CQ38303665-5F914A35-8C4A-490F-B30A-486C6B8EF7B2Q38623418-A40FEFA0-EDD1-463C-B55F-D01125131A57Q38856067-73678808-81F8-4767-A647-58A1B24DA741Q38856184-D94C9424-5B06-40FE-9AE7-A9E0BE9FA790Q39003207-CE5629BE-E187-42FC-B6CE-42DC98D7FE9AQ40520590-12DB6D4A-6F9A-4CC4-BC8D-F10D8FF63B82Q40536961-F24628FF-5AD9-4B82-81A6-A730D855A331Q40811463-487C4D6C-7193-419B-A509-53308B3D93DAQ41035415-8B6687FE-C1C2-48BB-86B5-A3A9D2AE20B6Q41412807-2535E311-EE9E-4DCF-96D6-34C086B14B04Q41846227-316A69FE-76E0-447D-B234-77CCC08028A7Q41859954-BE826B52-E82F-4456-A2B7-675FE25D13BAQ42795370-39440A3F-1A63-460B-A2EE-CF4F76E291B1Q42827837-E0EDE305-46D2-4213-A61B-AC451F780CC2Q42918493-0ADA1319-2924-4359-A57A-C0C6E90D7A2DQ44364032-B7539262-BBC4-4C36-9242-D60341D1845BQ44763257-0DCD8714-EB7E-4B9F-A9D1-D06C1A5B6F4AQ45776039-0CA7ABFA-1918-422D-8B3E-97F1947A2655Q45950505-D94728E4-5602-4D1E-AF4E-F792447BB65AQ46270187-052E1534-D4CF-42DA-99BD-C180B089712FQ46315786-AC9FB06F-33BA-4341-82E6-1B656861A186
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kumlesh K Dev
@nl
Kumlesh K Dev
@sl
Kumlesh K. Dev
@en
Kumlesh K. Dev
@es
type
label
Kumlesh K Dev
@nl
Kumlesh K Dev
@sl
Kumlesh K. Dev
@en
Kumlesh K. Dev
@es
altLabel
Kumlesh Dev
@en
prefLabel
Kumlesh K Dev
@nl
Kumlesh K Dev
@sl
Kumlesh K. Dev
@en
Kumlesh K. Dev
@es
P106
P1153
7004135414
P31
P496
0000-0003-4274-9119